companies / myrtellegtx-com
Generated UTC · publication cutoff 2026-11-09
Insufficient cited evidence for a two-sentence summary.
verified=2026-06-05 json
| total_raised | 55,162,63455.2M | ○ |
|---|---|---|
| founded | null | |
| hq | New York, New York | |
| industry | unknown | |
| stage | null |
Myrtelle develops gene therapies for myelin-based neurological disorders such as leukodystrophies that have few existing treatments. It serves patients with rare genetic white matter diseases of the central nervous system, with Canavan disease as its lead program.
No cited completed company acquisition recorded.
Dated disclosures. Customer relationships and classifications are historical; ARR is separate from revenue.
No cited disclosure recorded: named customer, disclosed revenue, ARR, count, B2B / B2C, sector, go-to-market.
No cited valuation with an explicit basis is recorded.
Historical post-money / actual annual or stated TTM revenue. Same currency; economic valuation date within 90 days of revenue period end, inclusive. No FX, ARR, annualized revenue, estimates or projections. Conflicts and ambiguous ties are withheld.
No qualifying pair recorded.
| date | type | amount | lead | src |
|---|---|---|---|---|
| 2025-12-23 | Funding round | 55,162,63455.2M | null | ○ |
addtoany, addtoany share buttons 1.1, contact form 7 6.1.5, facebook pixel, jquery 3.7.1, jquery migrate 3.4.1, mysql, nginx, php, pixelyoursite, python, slick
| fact | status | src |
|---|---|---|
| Funding round, $55.2M | attributed | ○ |
| existence | self-reported | WEB |
| description | self-reported | WEB |
| date | fact | change | src |
|---|---|---|---|
| 2026-09-25latest_round: seed, $55.2M, 2025-12-23 → Funding round, $55.2M, 2025-12-23, ○ 2026-06-05 | latest_round | seed, $55.2M, 2025-12-23 → Funding round, $55.2M, 2025-12-23 | ○ 2026-06-05 |
Records begin 2026-09-24. all_changes